Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 12:13:3627-3635.
doi: 10.2147/DMSO.S265399. eCollection 2020.

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza  1 , Kaleab Alemayehu Zewdie  1 , Bekalu Amare Tesfaye  1 , Selamawit Tesfamariam Gebrekirstos  1 , Derbew Fikadu Berhe  1
Affiliations
Review

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza et al. Diabetes Metab Syndr Obes. .

Abstract

Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan's effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.

Keywords: diabetes mellitus; hypertension; peroxisome proliferator-activated receptors; telmisartan.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Wienen W, Entzeroth M, van Meel JC, et al. A review on telmisartan: a novel, long‐acting angiotensin II‐receptor antagonist. Cardiovasc Drug Rev. 2000;18(2):127–154. doi:10.1111/j.1527-3466.2000.tb00039.x - DOI
    1. Sharpe M, Jarvis B, Goa KL. Telmisartan. Drugs. 2001;61(10):1501–1529. doi:10.2165/00003495-200161100-00009 - DOI - PubMed
    1. Galzerano D, Capogrosso C, Di Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010;6:113–133. doi:10.2147/VHRM.S7857 - DOI - PMC - PubMed
    1. Battershill AJ, Scott LJ. Telmisartan. Drugs. 2006;66(1):51–83. doi:10.2165/00003495-200666010-00004 - DOI - PubMed
    1. Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018;41(6):394–405. doi:10.1038/s41440-018-0040-6 - DOI - PMC - PubMed